Clinical Trials Logo

Filter by:
NCT ID: NCT01128595 Completed - Asthma Clinical Trials

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Start date: May 2010
Phase: Phase 2
Study type: Interventional

We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from allergic triggers in asthma

NCT ID: NCT01128153 Completed - Type 2 Diabetes Clinical Trials

Saxagliptin Triple Oral Therapy

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes and will be well tolerated.

NCT ID: NCT01127750 Completed - Clinical trials for Relapsing Multiple Sclerosis

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Start date: May 2010
Phase: Phase 3
Study type: Interventional

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

NCT ID: NCT01127633 Terminated - Alzheimer's Disease Clinical Trials

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

EXPEDITION EXT
Start date: December 2010
Phase: Phase 3
Study type: Interventional

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).

NCT ID: NCT01126437 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Start date: May 2010
Phase: Phase 3
Study type: Interventional

Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.

NCT ID: NCT01125800 Completed - Astrocytoma Clinical Trials

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Start date: February 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway. Phase II study is to assess preliminary efficacy in both adult and pediatric patients with recurrent or refractory MB.

NCT ID: NCT01125709 Completed - Clinical trials for Duchenne Muscular Dystrophy

Comparative Study of Clinical Endpoint in DMD: Handheld Myometry (HHM) Versus CINRG Quantitative Measurement System (CQMS)

Start date: January 2010
Phase: N/A
Study type: Observational

The aim of the proposed research is to compare two commonly used pediatric strength testing measures: handheld myometry (HHM) and CINRG Quantitative Measurement System (CQMS), with the goal of identifying a sensitive and valid tool for measuring muscle strength in children with DMD. The data obtained from this study will be used to make recommendations for strength measurement endpoints in prospective muscular dystrophy trials and provide more reliable and accurate recommendations in the clinic for strength assessment. This study will be performed at six participating sites in the Cooperative International Neuromuscular Research Group (CINRG).

NCT ID: NCT01125566 Completed - Breast Neoplasms Clinical Trials

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Start date: June 22, 2010
Phase: Phase 3
Study type: Interventional

To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (Herceptin®) treatment

NCT ID: NCT01125189 Completed - Hepatitis C Virus Clinical Trials

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

HEPCAT
Start date: July 2010
Phase: Phase 2
Study type: Interventional

To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than those with placebo.

NCT ID: NCT01124786 Completed - Clinical trials for Metastatic Pancreatic Adenocarcinoma

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.